Multiple Sclerosis Research Review, Issue 11

In this issue:

Ocrelizumab vs interferon beta-1a in relapsing MS
Ocrelizumab vs placebo in PPMS
Effect of immunomodulatory treatment withdrawal on the clinical course of SPMS
Higher latitude is associated with an earlier age of onset in MS
Brain MRI and subclinical abnormalities among asymptomatic individuals at risk for MS
Clinical + MRI markers enhances prediction of 12-year disability in MS
CSF biomarkers as measures of fingolimod efficacy in MS
Fatigue predicts disease worsening in RRMS
Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod
Peginterferon beta-1a reduces disability worsening in RRMS

Please login below to download this issue (PDF)